The sooner you can be evaluated, the better
Summary: The half-life of retatrutide is approximately 6 days, based on pharmacokinetic data from Phase 1 and Phase 2 clinical studies, which supports its once-weekly subcutaneous injection regimen
Their review, however, found that most of the evidence of such health effects was from rodent studies , and only three small pilot studies had looked at BPC-157 use in humans
Beyond glycaemic control, they slash cardiovascular risk by up to 26%, reduce the progression of kidney disease, and treat fatty liver and sleep apnoea, among others
By the time the third person told me they were taking it every second or third week and still maintaining their weight, I started recommending it to other patients, Biermann told The New York Times
Biol Trace Element Res (1995) 49(2-3):8595